NCT06302699View on ClinicalTrials.gov

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

May 1, 2024

Study Completion Date

March 1, 2026

Conditions
Multiple Myeloma
Trial Locations (1)

300020

RECRUITING

InsituteHBDH, Tianjin

All Listed Sponsors
collaborator

Suzhou Hongyuan Biotech Inc., Biobay, Suzhou, China.

UNKNOWN

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER